Realcan Pharmaceutical Group Co., Ltd. Class A

As of June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 3.70B, placing it among publicly traded companies globally. Its enterprise value stands at 3.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A has 1.50B shares outstanding.

As of June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 191.38. The price-to-sales ratio is 0.51, and the price-to-book ratio stands at 0.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.27B versus a market cap of 3.70B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 95.00, indicating elevated leverage, while an interest coverage ratio of -0.02 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A posted a return on equity (ROE) of 0.35, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.12, measuring how efficiently the asset base is converted into earnings. The company generates approximately 2.45M in revenue per employee across its workforce of 2,897.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.71 indicates how many times Realcan Pharmaceutical Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A recorded an income tax benefit of -60.98M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.57M and 19.07M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 1.36% over the past 52 weeks. The 50-day moving average sits at 3.24, while the 200-day moving average is 3.12.

Over the twelve months ended June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A generated 7.09B in revenue and converted that into 19.07M in net income, yielding earnings per share of 0.04. EBITDA reached -3.47M, while operating income came in at 44.98M.

As of June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A holds 5.75B in cash and equivalents against 5.18B in total debt, resulting in a net debt position of -742.72M. Total book value stands at 5.31B, with working capital of 788.12M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 9.50, reflecting its pricing power and cost economics. The operating margin of 0.63 and net profit margin of 0.27 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of 113.06 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -7.91, meaning Realcan Pharmaceutical Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Realcan Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on May 15, 2017 with a 10:23 split ratio.

As of June 30, 2026, Realcan Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 0.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.